Barad 2014.

Study characteristics
Methods	RCT Single centre USA
Participants	Women aged 18 to 38 years with normal endometrium undergoing fresh IVF. Exclusion criteria: women with renal disease, sickle cell disease, or a history of malignancy were considered ineligible for medical reasons.
Interventions	Intervention arm (N = 73): G‐CSF used was Nupogen (300 μg/1.0 mL, filgrastim; Amgen) Control arm (N = 68): placebo used (normal saline) 1 mL of G‐CSF or placebo (normal saline) was administered on the morning of hCG administration before noon by slow transcervical intrauterine infusion, similar in technique to an intrauterine insemination. Endometrial thickness was assessed by routine vaginal ultrasound before infusion and again 5 days later at the time of embryo transfer. Only data from pre‐cross‐over phase of the study was included.
Outcomes	Clinical pregnancy rate, implantation rate, miscarriage rate
Notes	Registered trial (NCT01202656). We contacted authors for clarification, who responded with data clarification and provided other details.
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	A computer‐generated randomisation table was used with separate randomisation blocks for women undergoing IVF and frozen‐embryo transfer in the first study cycle.
Allocation concealment (selection bias)	Low risk	Individual randomisation cards were sealed in numbered, opaque envelopes that were only accessible to the single staff member who administered the randomisation table and prepared the study materials.
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Treatment assignment was blinded to participants, physicians, and nursing staff.
Blinding of outcome assessment (detection bias) All outcomes	Low risk	The outcome assessors were also blinded.
Incomplete outcome data (attrition bias) All outcomes	Low risk	No dropouts during the first phase of the treatment, therefore considered to be at low risk of attrition bias
Selective reporting (reporting bias)	High risk	Live birth as a prespecified outcome (as per trial registry file) was not reported in the published manuscript.
Other bias	Low risk	None; funding mentioned (Foundation for Reproductive Medicine, a not‐for‐profit medical research foundation, and by intramural funds from the Center for Human Reproduction). No difference in baseline characteristics